Malignant progression in Barrett's esophagus: pathology and molecular biology.

Malignant progression in Barrett's esophagus: pathology and molecular biology. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Malignant progression in Barrett's esophagus: pathology and molecular biology. Abstract Text:

J Mueller,M Werner,J R Siewert,

Due to its increasing incidence, esophageal adenocarcinoma and its precursor lesions have received increasing attention in recent years. The histopathologic steps in the process of malignant progression in Barrett's esophagus are well described and include the following: (a) metaplasia of the normal esophageal squamous epithelium to a specialized intestinal glandular epithelium, (b) development of dysplasia (classified histologically as low and high grade), and (c) development of adenocarcinoma characterized by invasive and metastatic potential. Intestinal metaplasia can be identified by the presence of goblet cells, the detection of which can be aided by finding mucin stained by Alcian blue at low pH. Despite this well-characterized sequence, the timing of the development of dysplasia and the subsequent transition to carcinoma and the risk of development of carcinoma in low- and high-grade dysplasia are not precisely known. In addition, there are problems in the identification of dysplasia, including sampling error and interobserver discrepancies among pathologists. A better understanding of the mechanisms of these events would allow early identification and elimination of high-risk lesions before adenocarcinoma with its attendant poor prognosis were able to develop. In order to better understand this process and to potentially identify early markers of malignant transformation, a variety of molecular studies have been carried out in recent years on adenocarcinoma and its precursor lesions in Barrett's esophagus. On the phenotypic level, increased expression and changes in pattern of expression of proliferation marker (Mib-1) Ki-67 antigen, overexpression of p53 protein, overexpression of growth factors such as epidermal growth factor (EGF), c-erbB2, and transforming growth factor (TGF)-a, decreased and abnormal expression of the cell adhesion molecule E-cadherin, and, in carcinomas, increased expression of serine proteases have all been described. A new area of interest is the family of rab proteins, which play an important role in maintaining cell polarity in the gastrointestinal tract. Increased expression of one of these proteins, rab11, has been described in low-grade, but not high-grade dysplasia. In cytogenetic studies, an increased S-phase fraction, followed by an increased tetraploid (4N) fraction and then aneuploidy, has been described. So far, the specific genes which have been most thoroughly investigated have been p53, APC, p16, and the sites of probable tumor suppressor genes, including 3p (FHIT), 13q, and 18q. With only a few exceptions (i.e., rab11 expression, and possibly mutations of FHIT), the numerous molecular abnormalities which have been described occur late in malignant progression, which means that the best marker which presently exists to identify high-risk lesions in Barrett's esophagus is the histologic identification of dysplasia in endoscopic biopsies, especially high-grade dysplasia. We are presently beginning studies using laser microdissection and competitive genomic hybridization (CGH), which could help to identify new chromosomal areas that might contain genes that are crucial in the early phases of malignant progression in Barrett's esophagus. In the future, identification of such early molecular events which predispose to carcinoma development will allow more precise and earlier risk assessment for individual patients, therefore, enabling more effective therapy.

Malignant progression in Barrett's esophagus: pathology and molecular biology. Publishing Authors By Initials

J Mueller,M Werner,JR Siewert,

For similar proteins: neoplasm proteins research abstracts see: proteins: neoplasm proteins research

PUBMED ID PMID:

MEDLINE DATE:

Malignant progression in Barrett's esophagus: pathology and molecular biology. Journal Published:

PUBLICATION TYPE: Review

Journal: Recent results in cancer research. Fortschritte de

VOLUME: 155

Page Numbers: 29-41

Journal Abbreviation: Recent Results Cancer Res.

ISSN: 0080-0015

DAY: 13

MONTH: 02

YEAR: 2000

Malignant progression in Barrett's esophagus: pathology and molecular biology. Information

Number of References: 71

LANGUAGE: eng

NlmUniqueID: 44671

Malignant progression in Barrett's esophagus: pathology and molecular biology. Keywords Mesh Terms:

KEYWORDS: Neoplasm Proteins

MESH TERMS: metabolism

Chemical & Substance for Abstract: Malignant progression in Barrett's esophagus: pathology and molecular biology. Information

Substance Name: Neoplasm Proteins

Registry Number: 0

Grant and Affiliation Information for Malignant progression in Barrett's esophagus: pathology and molecular biology.

AFFILIATION: Chirurgische Klinik, Technische Universität München, Germany.

Country: GERMANY

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Recent Results Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Malignant progression in Barrett's esophagus: pathology and molecular biology Related Publications

• Detection of circulating tumor cells in blood using an optimized density gradient centrifugation.
• Fulminate intracardiac thrombosis associated with Budd-Chiari-syndrome and inferior vena cava thrombosis.
• Histopathological response after preoperative radiochemotherapy in rectal carcinoma is associated with improved overall survival.
• Malignant degeneration of Barrett's esophagus: clinical point of view.
• Malignant progression in Barrett's esophagus: pathology and molecular biology.
• Management of early esophageal cancer.
• Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer.
• Risk analysis in esophageal surgery.
• Stent implantation as a treatment option in patients with thoracic anastomotic leaks after esophagectomy.
• Telomere length and hTERT expression in patients with colorectal carcinoma.
• [Ambulatory surgery at the surgical clinic and polyclinic of the Munich Technical University]
• [Clinical significance of p53 tumor suppressor gene mutations in adenocarcinoma in Barrett esophagus]
• [Combined therapy of inoperable esophageal cancer]
• [Counter-indicated, unnecessary and superfluous surgical methods]
• [Diagnostic procedure in postoperative complications]
• [Extent of radical surgery in cardia carcinoma--esophagectomy or gastrectomy?]
• [Gastrointestinal hormones and lower esophageal sphincter]
• [Motility disorders as a pathogenetic principle: esophagus and cardia]
• [Motility disorders as a pathogenetic principle: introduction]
• [Possibilities of telecommunications in surgery]
• [Preoperative risk and postoperative follow-up in surgery of esophageal carcinoma]
• [Principles of radical surgery]
• [R1 resection in the surgery of upper gastrointestinal tumors : Relevance and therapeutic consequences.]
• [Reflux esophagitis from the surgical viewpoint]
• [Severe reflux esophagitis--conservative versus operative treatment. The surgical viewpoint]
• [Technical requirements and possibilities of teleconsultation in laparoscopic interventions]
• [The quality of life of patients with stomach and esophageal cancers]
• [Therapy of esophageal diverticula]
• [Trends in gastroenterologic intensive care medicine: suppurative cholangitis--surgery]
• [Value of clinical and experimental results for general practice in esophageal surgery]